mal de Debarquement
disease diseaseOn this page
Also known as disembarkment syndromeMal de debarquement syndromeMDDMdDSsickness of disembarkment
Summary
mal de Debarquement (MONDO:0016217) is a disease and 56 clinical trials. Top therapeutic interventions include citalopram, dextromethorphan, and brexpiprazole. A subtype of otorhinolaryngologic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Phenotypes (HPO): 17
- Clinical trials: 56
Clinical features
Signs & symptoms
Clinical features (HPO)
17 HPO clinical features (Orphanet curated; top 17 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0002141 | Gait imbalance | Frequent (30-79%) |
| HP:0002172 | Postural instability | Frequent (30-79%) |
| HP:0002317 | Unsteady gait | Frequent (30-79%) |
| HP:0002321 | Vertigo | Frequent (30-79%) |
| HP:0000496 | Abnormality of eye movement | Occasional (5-29%) |
| HP:0000622 | Blurred vision | Occasional (5-29%) |
| HP:0000651 | Diplopia | Occasional (5-29%) |
| HP:0000739 | Anxiety | Occasional (5-29%) |
| HP:0001289 | Confusion | Occasional (5-29%) |
| HP:0002013 | Vomiting | Occasional (5-29%) |
| HP:0002018 | Nausea | Occasional (5-29%) |
| HP:0002076 | Migraine | Occasional (5-29%) |
| HP:0002315 | Headache | Occasional (5-29%) |
| HP:0012378 | Fatigue | Occasional (5-29%) |
| HP:0030826 | Eyelid fasciculation | Occasional (5-29%) |
| HP:0007670 | Abnormal vestibulo-ocular reflex | Excluded (0%) |
| HP:0410263 | Brain imaging abnormality | Excluded (0%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | mal de Debarquement |
| Mondo ID | MONDO:0016217 |
| MeSH | C537840 |
| Orphanet | 210272 |
| ICD-11 | 459420954 |
| SNOMED CT | 446079007 |
| UMLS | C1608983 |
| MedGen | 345629 |
| GARD | 0006959 |
| MedDRA | 10064924 |
| NORD | 1394 |
| Is cancer (heuristic) | no |
Also known as: disembarkment syndrome · Mal de debarquement syndrome · MDD · MdDS · sickness of disembarkment
Disease family
This is a subtype of otorhinolaryngologic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › otorhinolaryngologic disease › mal de Debarquement
Related subtypes (39): bifid nose, autoimmune disease of ear, nose and throat, nasal disorder, atresia of external auditory canal and conductive deafness, external auditory canal atresia-vertical talus-hypertelorism syndrome, laryngeal abductor paralysis, larynx atresia, congenital velopharyngeal incompetence, microtia, congenital tracheal stenosis, laryngeal neuroendocrine neoplasm, arrhinia, laryngotracheal angioma, epignathus, nasolacrimal duct cyst, polyrrhinia, supernumerary nostril, proboscis lateralis, nasal glial heterotopia, nasal ganglioglioma, nasal encephalocele, isolated congenital syngnathia, cysts and fistulae of the face and oral cavity, isolated congenital nasal pyriform aperture stenosis, congenital nasal pyriform aperture stenosis with holoprosencephaly, middle ear anomaly, idiopathic bilateral vestibulopathy, juvenile nasopharyngeal angiofibroma, tracheal agenesis, semicircular canal dehiscence syndrome, hereditary otorhinolaryngologic disease, supratip dysplasia, recurrent respiratory papillomatosis, silent sinus syndrome, anotia, congenital tracheomalacia, disorder of pharynx, disorder of ear, lip and oral cavity squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 56.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 39 |
| PHASE2 | 6 |
| PHASE4 | 4 |
| PHASE3 | 4 |
| PHASE1 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01557946 | PHASE4 | COMPLETED | Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression |
| NCT02669030 | PHASE4 | UNKNOWN | A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia |
| NCT03126682 | PHASE4 | COMPLETED | Effect of Bupropion on Seizure Threshold in Depressed Patients |
| NCT04220996 | PHASE4 | COMPLETED | Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD) |
| NCT06698666 | PHASE3 | RECRUITING | Efficacy of Statins Among Major Depressive Disorder |
| NCT01152554 | PHASE3 | COMPLETED | A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder |
| NCT02013609 | PHASE3 | COMPLETED | Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment |
| NCT03765138 | PHASE3 | TERMINATED | Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression |
| NCT06132178 | PHASE2 | RECRUITING | Psilocybin rTMS for Treatment Resistant Depression |
| NCT06319378 | PHASE2 | RECRUITING | Cancer Related Major Depression Treated With a Single Dose of Psilocybin |
| NCT06828887 | PHASE2 | RECRUITING | Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD |
| NCT07562191 | PHASE2 | RECRUITING | Inhaled DMT for Major Depressive Disorder |
| NCT04880460 | PHASE2 | COMPLETED | Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients |
| NCT05657691 | PHASE2 | COMPLETED | Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) |
| NCT04226352 | PHASE1 | COMPLETED | Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder |
| NCT05528315 | PHASE1 | COMPLETED | SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects |
| NCT04612010 | EARLY_PHASE1 | WITHDRAWN | WAVES for Mal de Debarquement Syndrome |
| NCT05437588 | Not specified | RECRUITING | Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents |
| NCT06130371 | Not specified | RECRUITING | Stress, Inflammation and Neuroimaging in Major Depressive Disorder as Compared to Premenstrual Dysphoric Disorder |
| NCT06512324 | Not specified | ENROLLING_BY_INVITATION | Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry |
| NCT06572683 | Not specified | ENROLLING_BY_INVITATION | Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder |
| NCT06670040 | Not specified | ACTIVE_NOT_RECRUITING | Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder |
| NCT07111390 | Not specified | RECRUITING | Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD) |
| NCT07269964 | Not specified | RECRUITING | At-Home tDCS as Maintenance Therapy |
| NCT07422844 | Not specified | RECRUITING | Dynamic Network Response to TMS Treatment |
| NCT07439744 | Not specified | RECRUITING | NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status |
| NCT07572526 | Not specified | NOT_YET_RECRUITING | tDCS: Sleep to Mood in Depression (S2M-D) |
| NCT01344733 | Not specified | COMPLETED | A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD) |
| NCT01501812 | Not specified | UNKNOWN | Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders |
| NCT01808976 | Not specified | COMPLETED | Can Mental Health Apps Work in the Real World? A Feasibility Pilot Study. |
| NCT01913366 | Not specified | COMPLETED | Senior Peer Alliance for Rural Research On Wellness |
| NCT02339285 | Not specified | COMPLETED | Transcranial Alternating Current Stimulation for Major Depressive Disorder |
| NCT02470377 | Not specified | COMPLETED | Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome |
| NCT02540616 | Not specified | WITHDRAWN | Transcranial Electrical Stimulation for Mal de Debarquement Syndrome |
| NCT03083340 | Not specified | WITHDRAWN | Implementation of a Self-Help Depression Program Among Orthopedic Patients |
| NCT03754712 | Not specified | UNKNOWN | Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder |
| NCT03971305 | Not specified | UNKNOWN | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL |
| NCT03994081 | Not specified | COMPLETED | Mechanism of Action of tACS for the Treatment of MDD |
| NCT04071886 | Not specified | UNKNOWN | Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking Study |
| NCT04076644 | Not specified | COMPLETED | Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CITALOPRAM | 4 | 3 |
| DEXTROMETHORPHAN | 4 | 3 |
| BREXPIPRAZOLE | 4 | 1 |
| ORGOTEIN | 4 | 1 |
| SELEGILINE | 4 | 1 |
| SUVOREXANT | 4 | 1 |
| VORTIOXETINE | 4 | 1 |
| DEXMECAMYLAMINE | 3 | 2 |
| ICOSAPENT | 3 | 1 |
| PSILOCYBIN | 3 | 1 |
| MEBUFOTENIN | 2 | 1 |
| ABX-002 | 1 | 1 |
| CHEMBL498563 | 0 | 1 |